What does Mercury Biopharmaceutical Corporation do?

Mercury Biopharmaceutical Corporation (6932.TWO) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6932.TWO's market cap?

Mercury Biopharmaceutical Corporation (6932.TWO) has a market capitalization of approximately $2.24 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6932.TWO pay a dividend?

No — Mercury Biopharmaceutical Corporation (6932.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6932.TWO profitable?

Mercury Biopharmaceutical Corporation (6932.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6932.TWO

Mercury Biopharmaceutical Corporation

TWO·Drug Manufacturers, Specialty & Generic · Healthcare

NT$5.36NT$0.07−1.29%

Market capNT$2.24B·Aug 26 6:59 AM UTC

Price Chart

NT$5.36−NT$0.07 (−1.29%)today

−55.26%CAGR −19.66%

Select date range

FromTo

Dec 23, 2022Dec 23, 2022 → Aug 26, 2026· 3.7 yrsAug 26, 2026

Key Metrics

6932.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$0.00

Net Income−NT$51.62M

Net Margin—

Operating Cash Flow−NT$45.99M

Capital ExpendituresNT$11.12M

Free Cash Flow−NT$57.11M

Return on Equity−25.7%

Return on Invested Capital−9.6%

Net CashNT$93.69M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6932.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6932.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6932.TWO and 80,000+ other tickers.

About Mercury Biopharmaceutical Corporation

Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly…

CEO: Yaoren Liang
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: TWO
Employees: 21
Website: merdury.com

Peers

Peers Tab

4108.TW

PhytoHealth Corporation

Johnson Chemical Pharmaceutical Works Co., Ltd.

Cap

NT$2.6B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6932.TWO

What does Mercury Biopharmaceutical Corporation do?: Mercury Biopharmaceutical Corporation (6932.TWO) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6932.TWO's market cap?: Mercury Biopharmaceutical Corporation (6932.TWO) has a market capitalization of approximately $2.24 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6932.TWO pay a dividend?: No — Mercury Biopharmaceutical Corporation (6932.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6932.TWO profitable?: Mercury Biopharmaceutical Corporation (6932.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.